Senpivac-Plain (Epidural)/Senpivac-Heavy (Spinal)

Senpivac-Plain (Epidural)/Senpivac-Heavy (Spinal) Mechanism of Action

bupivacaine

Manufacturer:

Harson

Distributor:

Phil Pharmawealth
Full Prescribing Info
Action
Pharmacology: Pharmacodynamics: Senpivac-Heavy (Spinal): Bupivacaine, like other local anesthetics, causes a reversible blockade of impulses propagation along nerve fibers by preventing the inward movement of sodium ions through the nerve membrane. Local anesthetics of the amide type are thought to act within the sodium channels of the nerve membrane.
Pharmacokinetics: Bupivacaine (Senpivac) is about 95% bound to plasma proteins. Reported half-lives are from 1.5 to 5.5 hours in adults and about 8 hours in neonates. It is metabolized in the liver and is excreted in the urine principally as metabolites with only 5 to 6% as unchanged drug.
Bupivacaine is distributed into breast milk in small quantities. It crosses the placenta but the ratio of fetal concentrations to maternal concentrations is relatively low. Bupivacaine also diffuses into the CFS.
Absorption and Fate: Senpivac-Plain (Epidural): Bupivacaine is about 95% bound to plasma proteins. Reported half-lives include 1.5 to 5.5 hours in adults and about 8 hours in neonates. It is metabolized in the liver and is excreted in the urine principally as metabolites width only 5 to 6% as unchanged drug.
Bupivacaine is excreted into breast milk in small quantities and crosses the placenta but the ratio of fetal concentrations to maternal concentrations is relatively low. Bupivacaine also diffuses into the cerebrospinal fluid.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in